Clinical trial · Observational
Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes
Ataraxis Real-World Clinical Outcomes: A Prospective, Multi-Site, Observational Registry Linking AI-Based Pathology Scores With Short- and Long-Term Outcomes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Solid Tumor Malignancy | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ataraxis testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ataraxis testing
- description
- Adult patients with a solid tumor malignancy undergoing Ataraxis testing as part of routine clinical care. Treatment will be at the discretion of the physician.
- interventionNames
- Diagnostic Test: Ataraxis testing
Primary outcomes (1)
- measure
- A large-scale, multi-site registry linking Ataraxis test results with short- and long-term clinical outcomes
- timeFrame
- 10 years
- description
- Establish a prospective, multi-site registry of patients receiving Ataraxis tests, linking results with clinical outcomes to evaluate the real-world prognostic and predictive performance and clinical utility of Ataraxis tests.
Secondary outcomes (2)
- measure
- Performance and clinical utility of Ataraxis tests across diverse patient populations
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 years or older at the time of consent. * Diagnosis of a solid tumor malignancy, confirmed histologically or cytologically. * Patient is undergoing Ataraxis testing as part of their routine clinical care. * Availability of a pathology specimen. * Willing and able to provide written informed consent. Exclusion Criteria: * Unable or unwilling to provide informed consent. * Patient for whom an Ataraxis test result was not successfully generated (e.g., due to sample quality, technical failure, or any reason resulting in a non-reportable result).
References
Publications (0)
Data not yet available